Kaiser has been working with the company's management team and Board since March 2018.
He brings to Evecxia over three decades of biopharmaceutical drug development and commercialization expertise having most recently served as interim CEO of Cerecor Inc.
Kaiser also previously served as CEO of Denysias Bioscience, CBO at Acadia Pharmaceuticals and positions of increasing responsibilities over a 25+ year career at Eli Lilly and Company.
Evecxia is a privately funded, clinical stage pharmaceutical company co-founded by Duke neuro-psychopharmacologists, Dr. Marc Caron and Dr. Jacob Jacobsen.
The company is located in the Research Triangle Park, North Carolina
Evecxia's singular mission is to develop and commercialize EVX-101 to treat patients suffering from disabling, common, and costly neuropsychiatric conditions in which current therapies, in many cases, are sub-optimal.
Evecxia said it is the first company dedicated to realising the therapeutic potential of 5-hydroxytryptophan via specialized Rx combinations and drug delivery dosage forms.
EVX-101 is a unique and proprietary oral slow-release formulation of 5-hydroxytryptophan (5-HTP) and low-dose carbidopa. Initially, EVX-101 will be developed and positioned as a first-line adjunctive treatment in depressed patients responding inadequately to conventional antidepressants.
As an antidepressant, the development of EVX-101, a new chemical entity, is uniquely de-risked because the therapeutic mechanism, elevating extracellular serotonin beyond the effect of conventional SSRI/SNRI antidepressants, enjoys human proof-of-concept for efficacy and safety.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients